IDEX Corporation

Zacks Research raised its Q1 2027 EPS estimate to $2.09 and projects FY2027 EPS of $9.20 and FY2028 EPS of $10.27, reflecting confidence in continued earnings expansion. IDEX also beat its latest quarterly consensus by posting $2.00 EPS versus the $1.78 estimate, reinforcing the credibility of its upward earnings trajectory.

Despite the recent earnings beat, analysts remain cautious about whether IDEX can sustain this pace of EPS growth, particularly given macro headwinds in industrial markets. The consensus price target of $241.11 sits well above the current trading price of $219.80, suggesting meaningful skepticism about near-term execution risk.

Multiple analysts including TD Cowen, Citigroup, Stifel Nicolaus, and Seaport Research Partners have issued Buy ratings with price targets ranging from $250 to $260, well above current levels. The stock's strong fundamentals and consistent dividend payments support the case that current prices still offer upside potential.

IDEX shares have surged 28.7% year-to-date in 2026, significantly outperforming its sector. Analysts express concern that this rapid appreciation may have already priced in future growth, leaving limited room for further upside and increasing the risk of a valuation-driven correction.

Six of nine covering analysts rate IDEX a Buy, with a consensus price target of $241.11 implying meaningful upside from current levels. Firms like TD Cowen have recently raised their targets to $260, and Citigroup lifted its objective to $252, reflecting growing confidence in IDEX's operational and financial outlook.

Three analysts maintain a Hold rating, and market sentiment signals caution despite the positive EPS revisions. The gap between the current trading price of $219.80 and higher price targets suggests that a segment of the analyst community questions whether near-term catalysts are sufficient to close that valuation gap within the next twelve months.